Who owns MDGL? 13F holders and whale ownership
MDGL is tracked across public portfolios in Whale Analyzer. This page answers who owns MDGL, which top funds are buying MDGL, aggregate disclosed value, and recent position changes based on public data. Baker Bros. Advisors is the largest reported holder at $1.12B; the top five funds control 100.0% of reported ownership; institutions were net selling last quarter (0 increased, 1 reduced); the stock trades above the aggregate whale cost basis of $133.16. Top tracked holders include Baker Bros. Advisors and John Paulson.
Continue to the live MDGL dashboardTop holders
| Investor | Reported value | Shares | Change |
|---|---|---|---|
| Baker Bros. Advisors 13F portfolio Baker Bros. Advisors holdings | $1.12B | 2.1M | Held |
| John Paulson 13F portfolio Paulson & Co holdings | $728.8M | 1.4M | Reduced |
Ownership concentration
Reported ownership of MDGL is highly concentrated across tracked institutions.
- Single largest holder: 60.6% of reported ownership
- Top 5 holders: 100.0%
- Top 10 holders: 100.0%
Whale activity this quarter
Across 2 tracked institutions, 1 held, 1 reduced. Net positioning is net selling.
- Baker Bros. Advisors — Baker Bros. Advisors ($1.12B) (→ 0.0% qoq shares) · avg cost $104.36
- John Paulson — Paulson & Co ($728.8M) (▼ 18.5% qoq shares) · avg cost $165.49
Whale cost basis vs current price
The aggregate tracked cost basis is $133.16 versus a current price of $512.65, so MDGL trades above its cost basis (+285.0%). Average unrealized P&L across tracked holders: 300%.
Sector positioning — Health Care
MDGL sits within the Health Care sector alongside 221 other tracked names. Compare whale ownership across peers:
How to use this page
Values are reported public positions from tracked 13F filers and disclosures — not real-time ownership totals. Open the live MDGL dashboard for price charts and cross-investor scans, or read the SEC 13F guide.
Related stock holder pages
- INCY whale holders — Incyte Corporation
- BEIGF whale holders — BeOne Medicines Ltd.
- INSM whale holders — Insmed Incorporated
- ACAD whale holders — ACADIA Pharmaceuticals Inc.
- RVMDW whale holders — Revolution Medicines, Inc.
- CELC whale holders — Celcuity Inc.
- KOD whale holders — Kodiak Sciences Inc.
- KYMR whale holders — Kymera Therapeutics, Inc.
Learn more in Whale Analyzer Academy
Deepen your read on MDGL with these Whale Analyzer Academy guides:
Frequently asked questions
Who owns MDGL stock?
Whale Analyzer tracks 2 public institutional holders of MDGL with a combined reported value of $1.85B. See the holder table above for the largest tracked positions.
Which top funds are buying MDGL?
Tracked institutions were net selling last quarter — 1 held, 1 reduced. Check the "Change" column: "New" = fresh position, "Increased" = added, "Reduced" = trimmed.
How concentrated is MDGL ownership?
The top five tracked holders report 100.0% of aggregate ownership.
Is MDGL above or below the whale cost basis?
The aggregate tracked cost basis is $133.16 versus a current price of $512.65 (+285.0%).
What does 13F ownership mean for MDGL?
Use the interactive MDGL dashboard on Whale Analyzer for real-time holder analysis, or read our 13F Alpha Signals Guide.